Researched LJPC (La Jolla Pharma) all day.  This company just made a partnership with BMRN for rights to the Lupus (renal flares) drug Requent (which has had a long history of being tortured by the FDA-are you surprised).  Was trying to calculate the help it would be to BMRN PPS, but after researching I may actually buy some LJPC too?

 

Thinking of getting a nice block if it drops back and play the data results announcement that have been posted as due out before the end of Q1.  Not playing any FDA decision here.  They suck!  This could do an ACOR and go up10X if they meet those stats!  PPS about 1,25/share.

 

BMRN got involved and did due diligence on this play for 14 months (per their PR) and then committed.  I have lots of faith in BMRN's science for a small company as they already have 3 approved drugs themselves!  They have the touch IMO!

 

The tricky part about this one is the 1Q results can possibly come up short and a 2nd interim analysis is scheduled as a back-up at the end of Q2!  Meeting the stats goal ends the study and stimulates submission per the FDA SPA protocol agreement.  Can get strung along here?

 

If I get in, I play the data results and then move on.  Lots of big insider activity last year in big numbers.  Analysts Lazard seem to rag on this company all the time-accumulating or just have no faith in drug based on problem study results years ago?

 

Important to note there have been no Lupus drugs approved for renal flares in 40-50 years!  One drug that does not work well and corticosteroid treatment.

 

Like all baby bios its risky!  Interesting science!

 

Kutz